Zhao Yuanzhi, Qiu Conglong, Lin Ping, Yang Mei, Huang Ling, Zhao Zheng, Wu Xiangping, Zhou Dongsheng
Department of Psychiatry, Affiliated Kangning Hospital of Ningbo University, Ningbo, China.
Department of Psychiatry, Ningbo Kangning Hospital, Ningbo, China.
Front Aging Neurosci. 2025 Jan 8;16:1460853. doi: 10.3389/fnagi.2024.1460853. eCollection 2024.
Studies have shown the clinical effects of repetitive transcranial magnetic stimulation (rTMS) on depression in Alzheimer's disease (AD). However, the underlying mechanisms remain poorly understood. The measurement of brain activation links neurobiological and functional aspects but is challenging in patients with dementia. This study investigated the influence of rTMS on cortical activation in patients with AD and depressive symptoms, measured using functional near-infrared spectroscopy (fNIRS) during a verbal fluency task.
In this randomized, double-blind study, patients with AD and depression received either active rTMS (n = 17) or sham-rTMS (n = 16). Patients received 4 weeks of bilateral standard rTMS (1 Hz rTMS delivered to the right dorsolateral prefrontal cortex (DLPFC) and 10-Hz rTMS delivered to the left DLPFC).
No significant changes were found in the Mini-Mental State Examination (MMSE) and Modified Barthel Index (MBI); however, significant changes were found for the 17-item Hamilton Depression Rating Scale (HAMD-17) and the depression score of the Neuropsychiatric Inventory (NPI-depression; < 0.05). The results showed a decrease in the concentration of oxygenated hemoglobin, as measured with fNIRS, from baseline to week 4 in CH41 (in right DLPFC; = 0.0047, FDR-corrected). There was a negative correlation between the improvement in HAMD-17 severity in these patients and reduced oxygenated hemodynamic response of CH41 (r = - 0.504, = 0.039).
The results indicated a positive effect of rTMS on depression in patients with AD. The underlying cortical changes were imaged using fNIRS. Prefrontal activation measured by fNIRS is a potential biomarker for monitoring the response of patients with depression in AD to rTMS treatment.
研究已表明重复经颅磁刺激(rTMS)对阿尔茨海默病(AD)患者抑郁的临床疗效。然而,其潜在机制仍知之甚少。脑激活测量将神经生物学和功能方面联系起来,但对痴呆患者来说具有挑战性。本研究使用功能近红外光谱(fNIRS)在言语流畅性任务期间,调查了rTMS对伴有抑郁症状的AD患者皮质激活的影响。
在这项随机双盲研究中,患有AD和抑郁症的患者接受了活性rTMS(n = 17)或假rTMS(n = 16)。患者接受了4周的双侧标准rTMS(1赫兹rTMS施加于右侧背外侧前额叶皮质(DLPFC),10赫兹rTMS施加于左侧DLPFC)。
简易精神状态检查表(MMSE)和改良巴氏指数(MBI)未发现显著变化;然而,17项汉密尔顿抑郁评定量表(HAMD - 17)和神经精神科问卷的抑郁评分(NPI - 抑郁;<0.05)有显著变化。结果显示,通过fNIRS测量,从基线到第4周,CH41(右侧DLPFC;= 0.0047,经错误发现率校正)中氧合血红蛋白浓度下降。这些患者HAMD - 17严重程度的改善与CH41氧合血流动力学反应降低之间存在负相关(r = - 0.504,= 0.039)。
结果表明rTMS对AD患者的抑郁有积极作用。使用fNIRS对潜在的皮质变化进行了成像。通过fNIRS测量的前额叶激活是监测AD抑郁症患者对rTMS治疗反应的潜在生物标志物。